The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention

Sandeep Singla; Rajesh Sachdeva; Barry F Uretsky

doi:10.1016/j.jacc.2012.04.062

The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention

J Am Coll Cardiol. 2012 Nov 13;60(20):2005-16. doi: 10.1016/j.jacc.2012.04.062. Epub 2012 Oct 17.

Authors

Sandeep Singla¹, Rajesh Sachdeva, Barry F Uretsky

Affiliation

¹ University of Arkansas for Medical Sciences, Little Rock, AR, USA.

PMID: 23083781
DOI: 10.1016/j.jacc.2012.04.062

Abstract

Noncardiac surgery (NCS) may be required within the first year after percutaneous coronary intervention (PCI) in approximately 4% of patients and is the second most common reason for premature discontinuation of antiplatelet therapy (APT),which may, in turn, increase the risk of perioperative ischemic events, particularly stent thrombosis. Its continuation may increase the risk of perioperative bleeding. We review current information on the incidence of these events, particularly related to APT, describe potentially useful strategies to minimize the risks of adverse outcomes, and provide recommendations on APT use.

Publication types

Review

MeSH terms

Hemorrhage / chemically induced*
Humans
Incidence
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors / adverse effects*
Postoperative Complications / chemically induced
Postoperative Complications / etiology*
Risk Factors
Stents / adverse effects*
Thrombosis / etiology*

Substances

Platelet Aggregation Inhibitors